Over the Counter Profit Potential is Huge

May 30, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com -- According to the National Marketing Institute’s website, nearly 50% of Americans rely on supplements in their daily lives.  There are more than 80 therapeutic categories of OTC drugs, ranging from acne drug products to weight control drug products.  OTC medicines and supplements are an accepted and often first-line therapy and are recommended for many of the most common conditions and ailments affecting the U.S. population.

One OTC company selling OTC products you should start researching right away is Innovus Pharmaceuticals, Inc. (USOTC: INNV).

INNV markets over 35 products in the United States and in a range of countries around the world.  Its marketed products include FlutiCare® (the main competitor of Flonase on Amazon), GlucoGorx®, Zestra^®, EjectDelay^®, Sensum+^®, Zestra Glide^®, Vesele^®, PeVarx^®, Diabasens and Androferti^®.

Innovus Pharma also offers Beyond Human^® testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula™, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax^® and RecalMax^® nitric oxide strips for brain health; UriVarx^®, a supplement for overall bladder health and ProstaGorx^®, a supplement for prostate support

The company’s strength is its sales platform.  For example, their first product called Vesele  had sales of 200 units a year when they acquired it.  INNV was able to increase sales to close to $3.5M in one year.  INNV’s sales and marketing platform called Beyond Human targeting between 20-30 million consumers on a monthly basis.  With over 35 commercial products in multiple countries and a unique direct to consumer sales and marketing platform, the company has been doubling its revenue for the past three years.

The company just took on Regoxidine™, a topical foam containing 5% minoxidil that is approved by the FDA as a hair regrowth treatment and is used to grow hair on the top of the scalp.  The active ingredient is 5% minoxidil and is comparable to the Rogaine line.  Using their sales platform, this could be a big winner.

The companies we’re highlighting today include: Innovus Pharmaceuticals, Inc. (USOTC: INNV), OrganiGram Holdings (TSXV: OGI), Aphria (NYSE: APHA), The Green Organic Dutchman (TGODF), and Canopy Growth Corporation (NYSE: CGC).

Innovus Pharmaceuticals, Inc. (USOTC: INNV) (Market Cap: $5.601M; Share Price: $2.17), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, has had quite the start to the year: revenues of approximately $5.4 million, an increase of $0.8 million or 18.0% compared to prior year and $0.6 million or 12.8% compared to the prior quarter.  With annual 2019 net revenue projected to achieve record levels of $26-28 million, INNV is in a good position.

“We are encouraged by our start to the 2019 year with revenues increasing 18% and 12.8% in the comparable quarter in the prior year and the previous quarter, respectively. The Company has been able to strategically diversify its revenue channels during the quarter without significant disruption to overall revenue and achieving revenues from e-commerce platforms by approximately 30%. Additionally, with twelve products now approved by Health Canada, we are poised to focus more marketing efforts in Canada where we have historically experienced superior returns which we believe will help us achieve our goal of profitability,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

What investors may be most excited about however, is new CBD treatment.  The company launched first hemp-derived Cannabidiol product with MZS Sleeping Aid™.  Retailers like Walmart, Target, and Walgreens are getting in line to sell CBD products.  With hemp being legal through the new Farm Bill, this makes companies like INNV even more enticing.  Start your research today.

________

OrganiGram Holdings (TSXV: OGI) (Market Cap: $1.192B; Share Price: $7.69), a leading licensed producer of cannabis, announced that its common shares will commence trading on the Nasdaq Global Select Market under the symbol "OGI" on Tuesday May 21, 2019.  Organigram's common shares will continue to be listed and trade on the Toronto Venture Exchange (TSXV), also under the symbol "OGI".   

________

Aphria Inc. (NYSE: APHA) (Market Cap: $1.764B; Share Price: $7.00) shares fell after the Canadian cannabis company reported fiscal third-quarter results. It posted a C$108.2 million ($81.1 million) loss for its fiscal third quarter, or 43 cents a share, after a profit of C$12.9 million, or 8 cents a share, in the same period a year ago.  Revenue climbed to C$73.6 million from C$10.3 million in the first full quarter of Canadian legal cannabis.  But the company sold less cannabis than a year ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average retail selling price for medical cannabis increased to C$8.03 per gram from C$7.51, primarily because of higher oil sales. 

In April, it announced that the previously announced take-over bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to meet the statutory minimum tender condition and has now expired and is terminated.  As previously announced on April 15, 2019, the company entered into a definitive agreement with GGB to accelerate the expiry date of the Offer to April 25, 2019, as well as to terminate certain arrangements with GA Opportunities Corp. ("GAOC") for consideration of $89.0 million payable on future dates as set out in the April 15th press release.  The Offer is now expired and terminated and no longer open to any Aphria shareholder to tender their shares.  Accordingly, GGB will not be taking up any securities that may have been tendered to the Offer.  GGB will promptly return to the securityholder any Aphria shares tendered and not withdrawn during the period from the commencement of the Offer up to the expiry time of the Offer.  

________

The Green Organic Dutchman (TGODF) (Market Cap: $782.932M; Share Price: $2.90) recently participated in Virtual Investor Conferences. 

The Green Organic Dutchman is an Ontario, Canada, based marijuana company that was IPO’d in spring 2018 and is currently valued at $957 million.

The Green Organic Dutchman expects that its production capacity will be 170,000 kg marijuana a year, based on several deals that have expanded the company’s asset base during 2018.

This includes the June 2018 acquisition of a facility (approximately 280,000 square foot) that The Green Organic Dutchman plans to use for producing marijuana-containing edible products and marijuana-infused beverages.  It recently announced that effective March 25th, 2019 sales of certified-organic cannabis have started with national distribution to medical patients.  The Growers' Circle is a select group of patients across Canada now receiving TGOD's first certified-organic flower.  
________

Canopy Growth Corporation (NYSE: CGC) (Market Cap: $14.727B; Share Price: $42.48) signed an offtake agreement with PharmHouse Inc., a 49 per cent-owned joint venture of Canopy Rivers Inc. (CNOPOF).  Under the terms of the agreement, PharmHouse has agreed to allocate high quality cannabis flower from an additional 20 per cent of the flowering space available at its Leamington greenhouse facility over the next three years.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”).  Regal Consulting

has agreed to a three-month term consulting agreement with Innovus Pharmaceuticals, Inc. (INNV) signed 05/20/2019. The agreement calls for $20,000 in cash and 10,000 restricted 144 shares per month. All payments were made directly by Innovus Pharmaceuticals, Inc. to Regal Consulting, LLC to provide investor relations services, of which this article is a part of.  Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting.  INNV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein.  Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: microcapspeculators.com

OrganiGram (TSX:OGI)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

OrganiGram (TSX:OGI)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024